

#6

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. <b>5977-01-DRK</b>
In Re Application Of: <b>Cox, et al</b>			
Serial No. <b>09/936,680</b>	Filing Date <b>June 7, 2001</b>	Examiner <b>Not Yet Assigned</b>	Group Art Unit <b>Not Yet Assigned</b>
Title: <b>A NOVEL FAMILY OF BETA SUB-UNIT PROTEINS FROM A VOLTAGE-GATED SODIUM CHANNEL, NUCLEIC ACIDS ENCODING THEM AND THERAPEUTIC OF DIAGNOSTIC USES THEREOF</b>			
Address to: <b>Assistant Commissioner for Patents Washington, D.C. 20231</b>			
<b>37 CFR 1.97(b)</b>			
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.			
<b>37 CFR 1.97(c)</b>			
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:			
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);			
<b>OR</b>			
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).			

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 C.F.R. 1.97(b) or 1.97(c))

Docket No.  
5977-01-DRK

In Re Application: Cox, et al

Serial No.

09/936,680

Filing Date

June 7, 2001

Examiner

Not Yet Assigned

Group Art Unit

Not Yet Assigned

A NOVEL FAMILY OF BETA SUB-UNIT PROTEINS FROM A VOLTAGE-GATED SODIUM  
CHANNEL, NUCLEIC ACIDS ENCODING THEM AND THERAPEUTIC OF DIAGNOSTIC USES

## Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 23-0455  
as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

## Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit  
account is being facsimile transmitted to the United States  
Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

## Certificate of Mailing by First Class Mail


I certify that this document and fee is being deposited  
April 24, 2002 with the U.S. Postal Service  
as first class mail under 37 C.F.R. 1.8 and is  
addressed to the Assistant Commissioner for Patents,  
Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Nancy Dernbach

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by  
deposit account.



Signature

Eric J. Baude, Reg. No. 47,413

Dated: April 24, 2002

CC:

PTO/SB/08A (08-00)  
Approved through 10/31/2002 OMB 0651-0031  
U.S. Patent and Trademark U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information on this form if it contains a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	09 936,680
<b>Filing Date</b>	June 7, 2001
<b>First Named Inventor</b>	Cox et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	5977-01-DRK

(use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	5977-01-DRK
-------	---	----	---	------------------------	-------------

[illegible][illegible]

Examiner  
Signature

Date	
Considered	

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08B (08-00)  
Approved through 10/31/2002 OMB 0651-0031  
U. S. Patent and Trademark Office U. S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	09 936,680
Filing Date	June 7, 2001
First Named Inventor	Cox et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	5977-01-DRK

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Wiemann, et al., Toward A Catalog Of Human Genes And Proteins: Sequencing And Analysis of 500 Novel Complete Protein Coding Human cDNAs, Genome Research (2001) 11:422-435	
		Eubanks, J., et al., Structure and Chromosomal Localization of the B2 Subunit of the Human Brain Sodium Channel, NeuroReport 8, 2775-2779 (1997)	
		Nguyen, C., Localization of the Human NCAM Gene to Band q23 of Chromosome 11: The Third Gene Coding for a Cell Interaction Molecule Mapped to the Distal Portion of the Long Arm of Chromosome 11, J. Cell Biol., 102:711-715 (1986)	
		Qu, Y., et al., Modulation of cardiac Na <sup>+</sup> channel expression in Xenopus oocytes by beta 1-sub-units, Journal of Biological Chemistry, 270: 25696-25701 (1995)	
		Genbank Accession No.: AL136589; Homo sapiens mRNA GI: 13276680; 3/10/2001 (rev. 10/24/2001)	
		Genbank Accession No.: CAB66524; hypothetical protein [Homo sapiens] GI: 13276681; 3/10/2001 (rev. 10/24/2001)	
		Hirosawa, et al., Characterization of cDNA Clones Selected by the GeneMark Analysis from Size-Fractionated cDNA Libraries from Human Brain, DNA Research 6, 329-336 (1999)	
		Morgan, et al., B3: An Additional Auxiliary Subunit Of the Voltage-Sensitive Sodium Channel That Modulates Channel Gating With Distinct Kinetics, PNAS, Vol. 97, No. 5: 2308-2313 (2/29/2000)	
		Lee, et al., Comparative Expressed-Sequence-Tag Analysis of Differential Gene Expression Profiles in PC-12 Cells Before and After Nerve Growth Factor Treatment, Proc. Natl. Acad. Sci. USA, Vol. 92: 8303-8307 (1995)	
		Genebank Accession No.: AB032984; Homo sapiens mRNA for KIAA1158 protein, partial cds GI: 6330135; 11/11/1999 (rev. 10/24/2001)	
		Genebank Accession No.: AA685538 GI: 2672136; 12/9/1997 (rev. 10/24/2001)	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PTO/SB/21 (6-98)


Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1 style="text-align: center;">TRANSMITTAL FORM</h1> <p style="text-align: center;"><i>(to be used for all correspondence after initial filing)</i></p>		Application Number	09/936,680
		Filing Date	June 7, 2001
		First Named Inventor	Cox, et al
		Group Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission		Attorney Docket Number	5977-01-DRK

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">           Transmittal of Information and Disclosure Statement            All Cited References            Associate Power of Attorney            Return Postcard         </div>
<div style="border: 1px solid black; padding: 5px;">           Remarks         </div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Eric J. Baude, Reg. No. 47,413
Signature	
Date	4/24/02

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as <u>first class mail</u> in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <u>4/24/02</u>			
Typed or printed name		Nancy Dernbach	
Signature		Date	4/24/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.